BACKGROUND: Sensitized patients prior to heart transplantation are reportedly at risk for hyperacute rejection and for poor outcome after heart transplantation. It is not known whether the reduction of circulating antibodies pre-transplant alters post-transplant outcome. METHODS AND RESULTS: Between July 1993 and July 2003, we reviewed 523 heart transplant patients of which 95 had pre-transplant panel reactive antibody (PRAs) >10%; 21/95 were treated pre-transplant for circulating antibodies. These 21 patients had PRAs > 10% (majority 50-100%) and were treated with combination therapy including plasmapheresis, intravenous gamma globulin and rituximab to reduce antibody counts. The 74 untreated patients with PRAs > 10% (untreated sensitized group) and those patients with PRAs < 10% (control group) were used for comparison. Routine post-transplant immunosuppression included triple-drug therapy. After desensitization therapy, circulating antibody levels pre-transplant decreased from a mean of 70.5 to 30.2%, which resulted in a negative prospective donor-specific crossmatch and successful heart transplantation. Compared to the untreated sensitized group and the control group, the treated sensitized group had similar five-yr survival (81.1% and 75.7% vs. 71.4%, respectively, p = 0.523) and freedom from cardiac allograft vasculopathy (74.3% and 72.7% vs. 76.2%, respectively, p = 0.850). CONCLUSION: Treatment of sensitized patients pre-transplant appears to result in acceptable long-term outcome after heart transplantation.
BACKGROUND: Sensitized patients prior to heart transplantation are reportedly at risk for hyperacute rejection and for poor outcome after heart transplantation. It is not known whether the reduction of circulating antibodies pre-transplant alters post-transplant outcome. METHODS AND RESULTS: Between July 1993 and July 2003, we reviewed 523 heart transplant patients of which 95 had pre-transplant panel reactive antibody (PRAs) >10%; 21/95 were treated pre-transplant for circulating antibodies. These 21 patients had PRAs > 10% (majority 50-100%) and were treated with combination therapy including plasmapheresis, intravenous gamma globulin and rituximab to reduce antibody counts. The 74 untreated patients with PRAs > 10% (untreated sensitized group) and those patients with PRAs < 10% (control group) were used for comparison. Routine post-transplant immunosuppression included triple-drug therapy. After desensitization therapy, circulating antibody levels pre-transplant decreased from a mean of 70.5 to 30.2%, which resulted in a negative prospective donor-specific crossmatch and successful heart transplantation. Compared to the untreated sensitized group and the control group, the treated sensitized group had similar five-yr survival (81.1% and 75.7% vs. 71.4%, respectively, p = 0.523) and freedom from cardiac allograft vasculopathy (74.3% and 72.7% vs. 76.2%, respectively, p = 0.850). CONCLUSION: Treatment of sensitized patients pre-transplant appears to result in acceptable long-term outcome after heart transplantation.
Authors: J F McCarthy; D J Cook; N G Smedira; K J O'Malley; M G Massad; Y Sano; J B Young; R C Starling; N B Ratliff; P M McCarthy Journal: Transplant Proc Date: 1999 Feb-Mar Impact factor: 1.066
Authors: N Suciu-Foca; E Reed; C Marboe; P Harris; P X Yu; Y K Sun; E Ho; E Rose; K Reemtsma; D W King Journal: Transplantation Date: 1991-03 Impact factor: 4.939
Authors: J A Kobashigawa; A Sabad; D Drinkwater; G A Cogert; J D Moriguchi; N Kawata; M A Hamilton; A Hage; P Terasaki; H Laks Journal: Circulation Date: 1996-11-01 Impact factor: 29.690
Authors: B A Pisani; G M Mullen; K Malinowska; C E Lawless; J Mendez; M A Silver; R Radvany; J A Robinson Journal: J Heart Lung Transplant Date: 1999-07 Impact factor: 10.247
Authors: Charlotte Lawson; Angela L Holder; Rachel E Stanford; John Smith; Marlene L Rose Journal: Transplantation Date: 2005-07-27 Impact factor: 4.939
Authors: J Kobashigawa; L Miller; D Renlund; R Mentzer; E Alderman; R Bourge; M Costanzo; H Eisen; G Dureau; R Ratkovec; M Hummel; D Ipe; J Johnson; A Keogh; R Mamelok; D Mancini; F Smart; H Valantine Journal: Transplantation Date: 1998-08-27 Impact factor: 4.939
Authors: S Itescu; T C Tung; E M Burke; A Weinberg; N Moazami; J H Artrip; N Suciu-Foca; E A Rose; M C Oz; R E Michler Journal: Circulation Date: 1998-08-25 Impact factor: 29.690
Authors: Lois U Nwakanma; Jason A Williams; Eric S Weiss; Stuart D Russell; William A Baumgartner; John V Conte Journal: Ann Thorac Surg Date: 2007-11 Impact factor: 4.330
Authors: O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos Journal: Pharmacol Ther Date: 2012-01-16 Impact factor: 12.310
Authors: Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun Journal: Transpl Int Date: 2020-01 Impact factor: 3.782
Authors: Esme I Dijke; Jeffrey L Platt; Paul Blair; Menna R Clatworthy; Jignesh K Patel; A G Kfoury; Marilia Cascalho Journal: J Heart Lung Transplant Date: 2016-02-12 Impact factor: 10.247
Authors: Kathleen T Hickey; Lynn V Doering; Belinda Chen; Erik V Carter; Robert R Sciacca; David Pickham; Carmen Castillo; Nicole R Hauser; Barbara J Drew Journal: Eur J Cardiovasc Nurs Date: 2016-07-08 Impact factor: 3.908